Clinical pharmacodynamics of cannabinoids

The Handbook of Cannabis Therapeutics: From Bench to Bedside

Volumn , Issue , 2014, Pages 117-170

  Grotenhermen, Franjo ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872116893     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1300/5741_09     Document Type: Chapter

References (303)

1. Abadji, V., S. Lin, T. Gihan, G. Griffen, L.A. Stevenson, G.R. Pertwee, and A. Makriyannis. 1994. (R)-methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893.
2. Abood, M.E., C. Sauss, F. Fan, C.L. Tilton, and B.R. Martin. 1993. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 46(3):575-579.
3. Abrahamov, A., and R. Mechoulam. 1995. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56(23-24):2097-2102.
4. Abrams, D.I., R.J. Leiser, J.F. Hilton, S.B. Shade, T.A. Elbeik, F.A. Aweeka, J.A. Aberg, L.N. Benowitz, B.M. Bredt, S.G. Deeks, et al. 2001. Short-term effects of cannabinoids in patients with HIV infection. 2001 Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Asociation for Cannabis as Medicine, p. 7.
5. Adami, M., P. Frati, S. Bertini, A. Kulkarni-Narla, D.R. Brown, G. de Caro, G. Coruzzi, and G. Soldani. 2002. Gastric antisecretory role and immunohisto-chemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 135(7):1598-1606.
6. Adams, I.B., and B.R. Martin. 1996. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91(11):1585-1614.
7. Agurell, S., S. Carlsson, J.E. Lindgren, A. Ohlsson, H. Gillespie, and L. Hollister. 1981. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 37(10):1090-1092.
8. Al-Hayani, A., K.N. Wease, R.A. Ross, R.G. Pertwee, and S.N. Davies. 2001. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 41(8):1000-1005.
9. Anthony, J.C., L.A. Warner, and R.C. Kessler. 1994. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Experimental and Clin Psycho-pharmacol 2:244-268.
10. Archer, R.A., P. Stark, and L. Lemberger. 1986. Nabilone. In R. Mechoulam (ed.), Cannabinoids as therapeutic agents (pp. 85-103). Boca Raton: CRC Press.
11. Arevalo-Martin, A., J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza. 2003. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23(7):2511-2516.
12. Bachs, L., and H. Morland. 2001. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 124(2-3):200-203.
13. Baek, S.H., Y.O. Kim, J.S. Kwag, K.E. Choi, W.Y. Jung, and D.S. Han. 1998. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 21(3):353-356.
14. Baker, D., G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, A. Makriyannis, A. Khanolkar, L. Layward, F. Fezza, T. Bisogno, and V. Di Marzo. 2001. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15(2): 300-302.
15. Barann, M., G. Molderings, M. Bruss, H. Bonisch, B.W. Urban, and M. Gothert. 2002. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137(5):589-596.
16. 9-tetrahydrocannabinol in mice. Drug Alcohol Depend 60(2): 113-119.
17. Beal, J.E., R. Olson, L. Laubenstein, J.O. Morales, P. Bellman, B. Yangco, L. Lefkowitz, Plasse T.F., and Shepard K.V. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10(2):89-97.
18. Beal, J.E., R. Olson, L. Lefkowitz, L. Laubenstein, P. Bellman, B. Yangco, J.O. Morales, R. Murphy, W. Powderly, T.F. Plasse, et al. 1997. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14(1):7-14.
19. Beaulieu, P., T. Bisogno, S. Punwar, W.P. Farquhar-Smith, G. Ambrosino, V. Di Marzo, and A.S. Rice. 2000. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396(2-3):85-92.
20. Beltramo, M., N. Stella, A. Calignano, S.Y. Lin, A. Makriyannis, and D. Piomelli. 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277(5329):1094-1097.
21. Benowitz, N.L., and R.T. Jones. 1975. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 18(3):287-297.
22. Bisogno, T., L. Hanus, L. De Petrocellis, S. Tchilibon, D.E. Ponde, I. Brandi, A.S. Moriello, J.B. Davis, R. Mechoulam, and V. Di Marzo. 2001. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134(4):845-852.
23. Blazquez, C., M.L. Casanova, A. Planas, T.G. Del Pulgar, C. Villanueva, M.J. Fernandez-Acenero, J. Aragones, J.W. Huffman, J.L. Jorcano, and M. Guzman. 2003. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17(3):529-531.
24. Bonz, A., M. Laser, S. Kullmer, S. Kniesch, J. Babin-Ebell, V. Popp, G. Ertl, and J.A. Wagner. 2003. Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41(4):657-664.
25. Bornheim, L.M., and M.P. Grillo. 1998. Characterization of cytochrome P450 3A inactivation by cannabidiol: Possible involvement of cannabidiol-hydroxy-quinone as a P450 inactivator. Chem Res Toxicol 11(10):1209-1216.
26. Bornheim, L.M., K.Y. Kim, J. Li, B.Y. Perotti, and L.Z. Benet. 1995. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 23(8):825-831.
27. Braida, D., M. Pozzi, R. Cavallini, and M. Sala. 2001. Conditioned place preference induced by the cannabinoid agonist CP 55, 940: Interaction with the opioid system. Neuroscience 104(4):923-926.
28. Breivogel, C.S., G. Griffin, V. Di Marzo, and B.R. Martin. 2001. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60(1): 155-163.
29. Brenneisen, R., A. Egli, M.A. Elsohly, V. Henn, Y. Spiess. 1996. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. Int J Clin Pharmacol Ther 34(10):446-452.
30. British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers.
31. Brody, S., and R. Preut. 2002. Cannabis, tobacco, and caffeine use modify the blood pressure reactivity protection of ascorbic acid. Pharmacol Biochem Behav 72(4): 811-816.
32. Bueb, J.L., D.M. Lambert, and E.J. Tschirhart. 2001. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 1538(2-3):252-259.
33. Burstein, S. 1999. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 82(1):87-96.
34. Burstein, S. 2002. Therapeutic potential of ajulemic acid (CT3). In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 381-388). Binghamton, NY: The Haworth Press.
35. Burstein, S., C.A. Audette, S.A. Doyle, K. Hull, S.A. Hunter, and V. Latham. 1989. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid. J Pharmacol Exp Ther 251(2):531-535.
36. Burstein, S., S.A. Hunter, V. Latham, and L. Renzulli. 1987. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice. Experientia 43(4):402-403.
37. Cabral, G. 2002. Immune system. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 279-288). Binghamton, NY: The Haworth Press.
38. Calhoun, S.R., G.P. Galloway, and D.E. Smith. 1998. Abuse potential of dronabinol (Marinol). J Psychoactive Drugs 30(2):187-196.
39. Calignano, A., I. Katona, F. Desarnaud, A. Giuffrida, G. La Rana, K. Mackie, T.F. Freund, and D. Piomelli. 2000. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 408(6808):96-101.
40. Carley, D.W., S. Paviovic, M. Janelidze, and M. Radulovacki. 2002. Functional role for cannabinoids in respiratory stability during sleep. Sleep 25(4):391-398.
41. Casanova, M.L., C. Blazquez, J. Martinez-Palacio, C. Villanueva, M.J. Fernandez-Acenero, J.W. Huffman, J.L. Jorcano, and M. Guzman. 2003. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111(1):43-50.
42. Chan, P.C., R.C. Sills, A.G. Braun, J.K. Haseman, and J.R. Bucher. 1996. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30(1):109-117.
43. Chang, M.C., D. Berkery, R. Schuel, S.G. Laychock, A.M. Zimmerman, S. Zimmerman, and H. Schuel. 1993. Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 36(4):507-516.
44. Chapman, V. 1999. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br J Pharmacol 127(8):1765-1767.
45. Cichewicz, D.L., and E.A. McCarthy. 2003. Antinociceptive synergy between Δ9-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 304(3):1010-1015.
46. Cichewicz, D.L., and S.P. Welch. 2003. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Δ 9-THC. J Pharmacol Exp Ther 305(3):812-817.
47. Citron, M.L., T.S. Herman, F. Vreeland, S.H. Krasnow, and B.E. Fossieck, Jr. 1985. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 69:109-112.
48. Clermont-Gnamien, S., S. Atlani, N. Attal, F. Le Mercier, F. Guirimand, and L. Brasseur. 2002. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain] [Article in French]. Presse Med 31(39 Pt 1): 1840-1845.
49. Clifford, D.B. 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13(6):669-671.
50. Colasanti, B.K. 1990. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 6(4):259-269.
51. Colasanti, B.K., R.E. Brown, and C.R. Craig. 1984. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 15(6):479-484.
52. Consroe, P., R. Sandyk, and S.R. Snider. 1986. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30(4):277-282.
53. Coruzzi, G., M. Adami, G. Coppelli, P. Frati, and G. Soldani. 1999. Inhibitory effect of the cannabinoid receptor agonist WIN 55, 212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 360(6):715-718.
54. Costa, B., G. Giagnoni, S. Conti, D. Parolaro, and M. Colleoni. 2003. Cannabidiol is an oral effective therapeutic agent both in acute inflammation and in chronic FCA-induced arthritis. First European Workshop on Cannabinoid Research. Madrid (Spain).
55. Costa, B., D. Parolaro, and M. Colleoni. 1996. Chronic cannabinoid, CP-55, 940, administration alters biotransformation in the rat. Eur J Pharmacol 313(1-2): 17-24.
56. Cravatt, B.F., K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman. 2001. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98(16):9371-9376.
57. Crawford, W.J., and J.C. Merritt. 1979. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17(5):191-196.
58. Croxford, J.L., and S.D. Miller. 2003. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55, 212. J Clin Invest 111(8):1231-1240.
59. Dansak, D.A. 1997. As an antiemetic and appetite stimulant in cancer patients. In M.L. Mathre (ed.), Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana (pp. 69-83). Jefferson, NC: McFarland and Co.
60. Darmani, N.A. 2001. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 69(1-2):239-249.
61. Davis, J.P., and H.H. Ramsey. 1949. Antiepileptic action of marijuana active substances. Fed Proc 8:284.
62. De Petrocellis, L., D. Melck, T. Bisogno, A. Milone, and V. Di Marzo. 1999. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: Possible role in the feeding response. Neuroscience 92(1):377-387.
63. De Petrocellis, L., D. Melck, A. Palmisano, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo. 1998. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95(14):8375-8380.
64. Devane, W.A., L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946-1949.
65. Dewey, W.L. 1986. Cannabinoid pharmacology. Pharmacol Rev 38(2):151-178.
66. Di Marzo, V. 1998. "Endocannabinoids" and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1392(2-3):153-175.
67. 9-tetrahydrocannabinol-tolerant rats. J Neurochem 74(4):1627-1635.
68. Di Marzo, V., C.S. Breivogel, Q. Tao, D.T. Bridgen, R.K. Razdan, A.M. Zimmer, A. Zimmer, and B.R. Martin. 2000. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75(6):2434-2444.
69. Di Marzo, V., S.K. Goparaju, L. Wang, J. Liu, S. Batkai, Z. Jarai, F. Fezza, G.I. Miura, R.D. Palmiter, T. Sugiura, and G. Kunos. 2001. Leptin-regulated endo-cannabinoids are involved in maintaining food intake. Nature 410(6830):822-825.
70. Di Marzo, V., G. Griffin, L. De Petrocellis, I. Brandi, T. Bisogno, W. Williams, M.C. Grier, S. Kulasegram, A. Mahadevan, R.K. Razdan, and B.R. Martin. 2002. A structure/activity relationship study on arvanil, an endocannabinoid and vanil-loid hybrid. J Pharmacol Exp Ther 300(3):984-991.
71. Di Marzo, V., M.P. Hill, T. Bisogno, A.R. Crossman, and J.M. Brotchie. 2000. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14(10):1432-1438.
72. Dinh, T.P., T.F. Freund, and D. Piomelli. 2002. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivaion. Chem Phys Lipids 121(1-2):149-158.
73. Domino, E.F. 1999. Cannabinoids and the cholinergic system. In G. Nahas, K.M. Sutin, D.J. Harvey, and S. Agurell (eds.), Marihuana and medicine (pp. 223-226). Totowa, NJ: Humana Press.
74. Doyle, S.A., S.H. Burstein, W.L. Dewey, and S.P. Welch. 1990. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. Agents Actions 31(1-2):157-163.
75. Elsner, F., L. Radbruch, and R. Sabatowski. 2001. Tetrahydrocannabinol zur Therapie chronischer Schmerzen [Tetrahydrocannabinol for treatment of chronic pain]. Schmerz 15(3):200-204.
76. ElSohly, M.A. 2002. Chemical constituents of cannabis. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 27-36). Binghamton, NY: The Haworth Press.
77. Evans, A.T., E.A. Formukong, and F.J. Evans. 1987. Actions of cannabis constituents on enzymes of arachidonate, metabolism: anti-inflammatory potential. Biochem Pharmacol 36(12):2035-2037.
78. Fan, P. 1995. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73(2):907-910.
79. Fezza, F., T. Bisogno, A. Minassi, G. Appendino, R. Mechoulam, and V. Di Marzo. 2002. Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513(2-3):294-298.
80. Formukong, E.A., A.T. Evans, and F.J. Evans. 1989. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol 41(10):705-709.
81. Fowler, C.J., and S.O. Jacobsson. 2002. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide-targets for drug development? Prostaglandins Leukot Essent Fatty Acids 66(2-3):193-200.
82. Fowler, C.W. 2003. Biochemistry and pharmacology of fatty acid amide hydrolase, the enzyme responsible for the metabolism of anandamide and related N-acyl ethanolamines. First European Workshop on Cannabinoid Research. Madrid (Spain).
83. Fox, S.H., M. Kellett, A. P. Moore, A.R. Crossman, and J.M. Brotchie. 2002. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17(1):145-149.
84. Freemon, F.R. 1972. Effects of marihuana on sleeping states. JAAMA 220(10):1364-1365.
85. Fride, E., J. Barg, R. Levy, D. Saya, E. Heldman, R. Mechoulam, and Z. Vogel. 1995. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 272(2):699-707.
86. Fride, E., A. Foox, E. Rosenberg, M. Faigenboim, V. Cohen, L. Barda, H. Blau, and R. Mechoulam. 2003. Milk intake and survival in newborn cannabinoid CB(1) receptor knockout mice: Evidence for a "CB(3)" receptor. Eur J Pharmacol 461(1):27-34.
87. Fride, E., and E. Shohami. 2002. The endocannabinoid system: Function in survival of the embryo, the newborn and the neuron. Neuroreport 13(15):1833-1841.
88. Fried, P.A., B. Watkinson, and R. Gray. 1998. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 20(3):293-306.
89. Galiègue, S., S. Mary, J. Marchand, D. Dussossoy, D. Carrière, P. Carayon, M. Bouaboula, D. Shire, G. Le Fur, and P. Casellas. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
90. Galve-Roperh, I., C. Sanchez, M.L. Cortes, T.G. del Pulgar, M. Izquierdo, and M. Guzman. 2000. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6(3):313-319.
91. Gaoni, Y., and R. Mechoulam. 1964. Isolation, structure and partial synthesis of the active constituent of hashish. J Am Chem Soc 86:1646-1647.
92. Gardner, E.L. 2002. Addictive potential of cannabinoids: The underlying neuro-biology. Chem Phys Lipids 121(1-2):267-290.
93. Georgotas, A., and P. Zeidenberg. 1979. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 20(5):427-432.
94. Gieringer, D. 2002. Medical use of cannabis: Experience in California. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 143-151). Binghamton, NY: The Haworth Press.
95. Gilson, I., and M. Busalacchi. 1998. Marijuana for intractable hiccups. Lancet 351 (9098):267.
96. Giuffrida, A., M. Beltramo, and D. Piomelli. 2001. Mechanisms of endocanna-binoid inactivation: Biochemistry and pharmacology. J Pharmacol Exp Ther 298(1):7-14.
97. Glaser, S.T., N.A. Abumrad, F. Fatade, M. Kaczocha, K.M. Studholme, D.G. Deutsch. 2003. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100(7):4269-4274.
98. s linkage to the CB1 receptor. J Neurosci 17:5327-5333.
99. Gordon, E., and O. Devinsky. 2001. Alcohol and marijuana: Effects on epilepsy and use by patients with epilepsy. Epilepsia 42(10):1266-1272.
100. Green, K., E.C. Kearse, and O.L. McIntyre. 2001. Interaction between Delta-9-tetrahydrocannabinol and indomethacin. Ophthalmic Res 33(4):217-220.
101. Grinspoon, L., and J.B. Bakalar. 1993. Marihuana, the forbidden medicine. New Haven, CT: Yale University Press.
102. Grinspoon, L., and J.B. Bakalar. 1998. The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research. J Psy-choactive Drugs 30(2):171-177.
103. Grotenhermen, F. 2002a. Effects of cannabis and the cannabinoids. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 55-66). Binghamton, NY: The Haworth Press.
104. Grotenhermen, F. 2002b. Review of therapeutic effects. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 123-142). Binghamton, NY: The Haworth Press.
105. Grotenhermen, F. 2002c. Review of unwanted actions of Cannabis and THC. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 233-245). Binghamton, NY: The Haworth Press.
106. Grotenhermen, F., and E. Russo (eds.). 2002. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. Binghamton, NY: The Haworth Press.
107. Grundy, R.1.2002. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11(10):1365-1374.
108. Guzman, M., C. Sanchez, and I. Galve-Roperh. 2001. Control of the cell survival/death decision by cannabinoids. J Mol Med 78(11):613-625.
109. Hall, W., N. Solowij, and J. Lemon. 1994. The health and psychological consequences of cannabis use. Canberra: Commonwealth Department of Human Services and Health, Monograph Series No. 25.
110. Hampson, A. 2002. Cannabinoids as neuroprotectants against ischemia. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 101-110). Binghamton, NY: The Haworth Press.
111. Hampson, R.E., and S.A. Deadwyler. 1999. Cannabinoids, hippocampal function and memory. Life Sci 65:715-723.
112. Haney, M., A. Bisaga, and R.W. Foltin. 2003. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 166(1):77-85.
113. Hanus, L., S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, D.E. Shalev, I. Kustanovich, and R. Mechoulam. 2001. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98(7):3662-3665.
114. Hart, C.L., A.S. Ward, M. Haney, S.D. Comer, R.W. Foltin, and M.W. Fischman. 2002. Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 164(4):407-415.
115. Hartley, J.P., S.G. Nogrady, and A. Seaton. 1978. Bronchodilator effect of delta1-tetrahydrocannabinol. Br J Clin Pharmacol 5(6):523-525.
116. Hembree 3d, W.C., G.G. Nahas, P. Zeidenberg, and H.F. Huang. 1978. Changes in human spermatozoa associated with high dose marihuana smoking. Adv Biosci 22-23:429-439.
117. Hemming, M., and P.M. Yellowlees. 1993. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 7:389-391.
118. Hepler, R.S., and I.R. Frank. 1971. Marihuana smoking and intraocular pressure. JAMA 217(10):1392.
119. Hepler, R.S., and R.J. Petrus. 1976. Experiences with administration of marihuana to glaucoma patients. In S. Cohen and R.C. Stillman (eds.), The therapeutic potential of marihuana (pp. 63-75). New York: Plenum Medical Book.
120. Heyser, C.J., R.E. Hampson, and S.A. Deadwyler. 1993. Effects of delta-9-tetra-hydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264(1):294-307.
121. Holdcroft, A., M. Smith, A. Jacklin, H. Hodgson, B. Smith, M. Newton, and F. Evans. 1997. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52(5):483-486.
122. Hollister, L.E. 1986. Health aspects of cannabis. Pharmacological Reviews 38:1-20.
123. 9-THC with other drugs. In G. Nahas, K.M. Sutin, D.J. Harvey, and S. Agurell (eds.), Marihuana and medicine (pp. 273-277). Totowa, NJ: Humana Press.
124. House of Lords Select Committee on Science and Technology. 1998. Cannabis. The scientific and medical evidence. London: The Stationery Office.
125. Howlett, A.C. 2002. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69:619-631.
126. Huang, S.M., T. Bisogno, M. Trevisani, A. Al-Hayani, L. De Petrocellis, F. Fezza, M. Tognetto, T.J. Petros, J.F. Krey, C.J. Chu, et al. 2002. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99(12):8400-8405.
127. Huestis, M.A., D.A Gorelick, S.J. Heishman, K.L. Preston, R.A. Nelson, E.T. Moolchan, and R.A. Frank. 2001. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58(4):322-328.
128. Hunt, C.A., R.T. Jones. 1980. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 215(1):35-44.
129. Hunt, C.A., R.T. Jones, R.I. Herning, and J. Bachman. 1981. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9(3):245-260.
130. Izzo, A.A., F. Fezza, R. Capasso, T. Bisogno, L. Pinto, T. Iuvone, G. Esposito, N. Mascolo, V. Di Marzo, and F. Capasso. 2001. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 134(3):563-570.
131. Izzo, A.A., L. Pinto, F. Borrelli, R. Capasso, N. Mascolo, and F. Capasso. 2000. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 129(8):1627-1632.
132. Jacobsson, S.O., T. Wallin, and C.J. Fowler. 2001. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299(3):951-959.
133. Jaeger, W., L.Z. Benet, and L.M. Bornheim. 1996. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26(3):275-284.
134. Jaggar, S.I., F.S. Hasnie, S. Sellaturay, and A.S. Rice. 1998. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76(1-2):189-199.
135. Jain, A.K., J.R. Ryan, F.G. McMahon, and G. Smith. 1981. Evaluation of intramuscular levonantrodol and placebo in acute postoperative pain. Journal of Clinical Pharmacology 21(Suppl):320S-326S.
136. Jan, T.R., A.K. Farraj, J.R. Harkema, and N.E. Kaminski. 2003. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice small star, filled. Toxicol Appl Pharmacol 188(1):24-35.
137. Jatoi, A., H.E. Windschitl, C.L. Loprinzi, J.A. Sloan, S.R. Dakhil, J.A. Mailliard, S. Pundaleeka, C.G. Kardinal, T.R. Fitch, J.E. Krook, et al. 2002. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. JClin Oncol 20(2):567-573.
138. Jones, R.T., N. Benowitz, and J. Bachman. 1976. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 282:221-239.
139. Joy, J.E., S.J. Watson, and J.A. Benson. 1999. Marijuana and medicine: Assessing the science base. Washington DC: Institute of Medicine, National Academy Press.
140. Kalant, H., W. Corrigal, W. Hall, and R. Smart. 1999. The health effects of cannabis. Toronto (Canada): Centre for Addiction and Mental Health.
141. Karler, R., and S.A. Turkanis. 1981. The cannabinoids as potential antiepileptics. J Clin Pharmacol 21(8-9 Suppl):437S-448S.
142. Karler, R., and S.A. Turkanis. 1987. Different cannabinoids exhibit different pharmacological and toxicological properties. NIDA Res Monogr 79:96-107.
143. Kathuria, S., S. Gaetani, D. Fegley, F. Valino, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. La Rana, A. Calignano, et al. 2003. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9(1):76-81.
144. Kelly, T.H., R.W. Foltin, C.S. Emurian, and M.W. Fischman. 1993. Performance-based testing for drugs of abuse: Dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 17(5):264-272.
145. Killestein, J., E.L. Hoogervorst, M. Reif, N.F. Kalkers, A.C. Van Loenen, P.G. Staats, R.W. Gorter, B.M. Uitdehaag, and C.H. Polman. 2002. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58(9):1404-1407.
146. Kleiber, D., R. Soellner, and P. Tossmann. 1997. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren. Bonn: Federal Ministry of Health.
147. Knoller, N., L. Levi, I. Shoshan, E. Reichenthal, N. Razon, Z.H. Rappaport, and A. Biegon. 2002. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30(3):548-554.
148. Koe, B.K., G.M. Milne, A. Weissman, M.R. Johnson, and L.S. Melvin. 1985. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol 109(2):201-212.
149. Kosel, B.W., F.T. Aweeka, N.L. Benowitz, S.B. Shade, J.F. Hilton, P.S. Lizak, and D.I. Abrams. 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16(4):543-550.
150. Laine, K., K. Jarvinen, and T. Jarvinen. 2003. Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci 72(7):837-842.
151. Lake, K.D., D.R. Compton, K. Varga, B.R. Martin, and G. Kunos. 1997. Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281:1030-1037.
152. Lane, M., C.L. Vogel, J. Ferguson, S. Krasnow, J.L. Saiers, J. Hamm, K. Salva, P.H. Wiernik, C.P. Holroyde, S. Hammill, et al. 1991. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6(6):352-359.
153. Lemberger, L., R.E. Crabtree, and H.M. Rowe. 1972. 11-hydroxy-Δ9-tetrahydro-cannabinol: Pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 177(43):62-64.
154. Leweke, F.M., A. Giuffrida, U. Wurster, H.M. Emrich, and D. Piomelli. 1999. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10(8):1665-1669.
155. Lichtman, A.H., S.M. Sheikh, H.H. Loh, and B.R. Martin. 2001. Opioid and canna-binoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298(3):1007-1014.
156. Lissoni, P., M. Resentini, R. Mauri, D. Esposti, G. Esposti, D. Rossi, G. Legname, and F. Fraschini. 1986. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res 18(1):77-78.
157. Little, P.J., D.R. Compton, R. Mechoulam, and B. Martin. 1989. Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 32:661-666.
158. Liu, J., H. Li, S.H. Burstein, R.B. Zurier, and J.D. Chen. 2003. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic canna-binoid ajulemic acid. Mol Pharmacol 63(5):983-992.
159. Loewe, S. 1950. Cannabiswirkstoffe und Pharmakologie der Cannabinole. Archiv für Experimentelle Pathologie und Pharmakologie 211:175-193.
160. Lorenz, R. 2002. A casuistic rationale for the treatment of spastic and myocloni in a childhood neurodegenerative disease: neuronal ceroid lipofuscinosis of the type Jansky-Bielschowsky. Neuroendocrinol Lett 23(5-6):387-390.
161. Lucraft, H.H., and M.K. Palmer. 1982. Randomized clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-indiced vomiting. Clin Radiol 33(6):621-622.
162. Luthra, Y.K., H.J. Esber, D.M. Lariviere, and H. Rosenkrantz. 1980. Assessment of tolerance to immunosuppressive activity of delta 9-tetrahydrocannabinol in rats. J Immunopharmacol 2(2):245-256.
163. Lyketsos, C.G., E. Garrett, K.Y. Liang, and J.C. Anthony. 1999. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 149(9):794-800.
164. Malfait, A.M., R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, R. Mechoulam, M. Feldmann. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97(17):9561-9566.
165. Martyn, C.N., L.S. Illis, and J. Thom. 1995. Nabilone in the treatment of multiple sclerosis. Lancet 345(8949):579.
166. Mathre, M.L. 1997. Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson, NC: McFarland and Co.
167. Mattes, R.D., L.M. Shaw, and K. Engelman. 1994. Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 19(2):125-140.
168. Maurer, M., V. Henn, A. Dittrich, and A. Hofmann. 1990. Delta-9-tetrahydro-cannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Neurol Sci 240(1):1-4.
169. McCallum, R.W., I. Soykan, K.R. Sridhar, D.A. Ricci, R.C. Lange, and M.W. Plankey. 1999. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: A double-blind, randomized study. Aliment Pharmacol Ther 13(1):77-80.
170. McPartland, J.M., and E.B. Russo. 2001. Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Ther 1(3/4):103-132.
171. Mechoulam, R. 1986. Cannabinoids as therapeutic agents. Boca Raton: CRC Press.
172. Mechoulam, R. 2002. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fatty Acids 66(2-3):93-99.
173. Mechoulam, R., S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, and D.R. Compton. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50(1):83-90.
174. Mechoulam, R., and L. Hanus. 2002. Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 121(1-2):35-43.
175. Mechoulam, R., and E. Shohami. 2002. HU-211: Cannabinoid Neuroprotective Agent. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 389-400). Binghamton, NY: The Haworth Press.
176. Mechoulam, R., E. Shohami, E. Fride, and I. Bab. 2003. The ubiquitous role of endocannabinoids in physiological processes: examples in neuroprotection, feeding and bone formation. First European Workshop on Cannabinoid Research. Madrid (Spain).
177. Meinck, H.M., P.W. Schonle, and B. Conrad. 1989. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236(2):120-122.
178. Melamede, R. 2002. Possible mechanisms in autoimmune diseases. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 111-122). Binghamton, NY: The Haworth Press.
179. Melck, D., L. De Petrocellis, P. Orlando, T. Bisogno, C. Laezza, M. Bifulco, and V. Di Marzo. 2000. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141(1):118-126.
180. Melvin, L.S., G.M. Milne, M.R. Johnson, B. Subramaniam, G.H. Wilken, and A.C. Howlett. 1993. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs. Mol Pharmacol 44(5):1008-1015.
181. Merritt, J.C., W.J. Crawford, P.C. Alexander, A.L. Anduze, and S.S. Gelbart. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87(3):222-228.
182. Merritt, J.C., J.L. Olsen, J.R. Armstrong, and S.M. McKinnon. 1981. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 33(1): 40-41.
183. Miczek, K.A., and B.N. Dixit. 1980. Behavioral and biochemical effects of chronic delta 9-tetrahydrocannabinol in rats. Psychopharmacology (Berl) 67(2):195-202.
184. Mikuriya, T.H. 1970. Cannabis substitution. An adjunctive therapeutic tool in the treatment of alcoholism. Med Times 98(4):187-191.
185. Mittleman, M.A., R.A. Lewis, M. Maclure, J.B. Sherwood, and J.E. Muller. 2001. Triggering myocardial infarction by marijuana. Circulation 103(23):2805-2809.
186. Moss, D.E., P.Z. Manderscheid, S.P. Montgomery, A.B. Norman, and P.R. Sanberg. 1989. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 44(21):1521-1525.
187. Müller-Vahl, K.R., H. Kolbe, and R. Dengler. 1997. Gilles de la Tourette-Syndrom. Einfluß von Nikotin, Alkohol und Marihuana auf die klinische Symptomatik [Gilles de la Tourette-Syndrom. Influence of nicotine, alcohol and marijuana on clinical symptoms] [published in German]. Nervenarzt 68:985-989.
188. Müller-Vahl, K.R., H. Prevedel, K. Theloe, H. Kolbe, H.M. Emrich, and U. Schneider. 2003. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsycho-pharmacology 28(2):384-388.
189. 9-tetrahy-drocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35(2):57-61.
190. Müller-Vahl, K.R., U. Schneider, H. Kolbe, and H.M. Emrich. 1999. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156(3): 495.
191. Müller-Vahl, K.R., U. Schneider, H. Prevedel, K. Theloe, H. Kolbe, T. Daldrup, and H.M. Emrich. 2003. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. JClin Psychiatry64(4): 459-465.
192. Murphy, L. 2002. Hormonal system and reproduction. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 289-298). Binghamton, NY: The Haworth Press.
193. Musty, R.E., P. Consroe. 2002. Spastic disorders. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 195-204). Binghamton, NY: The Haworth Press.
194. Notcutt, W., M. Price, R. Miller, S. Newport, C. Sansom, and S. Simmonds. 2001a. Medicinal cannabis extracts in chronic pain: (2) comparison of two patients with back pain and sciatica. 2001 Congress on Cannabis and the Cannabinoids, Co-logne, Germany: International Association for Cannabis as Medicine, p. 25.
195. Notcutt, W., M. Price, R. Miller, S. Newport, C. Sansom, and S. Simmonds. 2001b. Medicinal cannabis extracts in chronic pain: (3) comparison of two patients with multiple sclerosis. 2001 Congress on Cannabis and the Cannabinoids, Cologne, Germany: International Association for Cannabis as Medicine, p. 26.
196. Noyes, R., D.A. Baram. 1974. Cannabis analgesia. Compreh Psychiatr 15:531-535.
197. Noyes, R. Jr, S.F. Brunk, D.A.H. Avery, and A.C. Canter. 1975. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18(1): 84-89.
198. Noyes, R. Jr, S.F. Brunk, D.A. Baram, and A. Canter. 1975. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15(2-3):139-143.
199. Nunez, L.A., and M. Gurpegui M. 2002. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand 105(3):173-178.
200. O'Leary, D.S., R.I. Block, J.A. Koeppel, M. Flaum, S.K. Schultz, N.C. Andreasen, L.B. Ponto, G.L. Watkins, R.R. Hurtig, and R.D. Hichwa. 2002. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26(6):802-816.
201. Ottani, A., and D. Giuliani. 2001. Hu 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 7(2):131-145.
202. Parker, L.A., R. Mechoulam, and C. Schlievert. 2002. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13(5):567-570.
203. Parker, L.A., R. Mechoulam, C. Schlievert, L. Abbott, M.L. Fudge, and P. Burton. 2003. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 166(2):156-162.
204. Pate, D. 2002. Glaucoma and cannabinoids. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 215-224). Binghamton, NY: The Haworth Press.
205. Perez-Reyes, M. 1999. The psychologic and physiologic effects of active canna-binoids. In G. Nahas, K.M. Sutin, D.J. Harvey, and S. Agurell (eds.), Marihuana and medicine (pp. 245-252). Totowa, NJ: Humana Press.
206. Perez-Reyes, M., S.H. Burstein, W.R. White, S.A. McDonald, and R.E. Hicks. 1991. Antagonism of marihuana effects by indomethacin in humans. Life Sci 48(6):507-515.
207. 9-tetra-hydrocannabinol to the brain of mice. In G.G. Nahas (eds.), Marihuana: Chemistry, biochemistry, and cellular effects (pp. 179-185). New York: Springer.
208. Perez-Reyes, M., M. Timmons, M. Lipton, K. Davis, and M. Wall. 1972. Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetra-hydrocannabinol. Science 177(49):633-635.
209. Pertwee, R. 1992. In vivo interactions between pschotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In L. Myrphy and A. Bartke (eds.), Marijuana/cannabinoids: Neurobiology and neurophysiology (pp. 165-218). Boca Raton, FL: CRC Press.
210. Pertwee, R.G. 1997. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129-180.
211. Pertwee, R.G. 1999a. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 65:597-605.
212. Pertwee, R.G. 1999b. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635-664.
213. Pertwee, R.G. 2002. Sites and Mechanisms of Action. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 73-88). Binghamton, NY: The Haworth Press.
214. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63(1):PL1-PL6.
215. Petro, D.J. 1980. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 21(1):81, 85.
216. Petro, D.J., and C. Ellenberger Jr. 1981. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21(8-9 Suppl):413S-416S.
217. Plasse, T.F., R.W. Gorter, S.H. Krasnow, M. Lane, K.V. Shepard, and R.G. Wadleigh. 1991. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40(3):695-700.
218. Pope, H.J. 2002. Cannabis, cognition, and residual confounding. JAMA 287(9): 1172-1174.
219. Pope, H.G., A.J. Gruber, J.I. Hudson, G. Cohane, M.A. Huestis, and D. Yurgelun-Todd. 2003. Early-onset cannabis use and cognitive deficits: What is the nature of the association? Drug Alcohol Depend 69(3):303-310.
220. Pope, H.G. Jr., A.J. Gruber, J.I. Hudson, M.A. Huestis, and D. Yurgelun-Todd. 2001. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58(10):909-915.
221. Porter, A.C., J.M. Sauer, M.D. Knierman, G.W. Becker, M:J. Berna, J. Bao, G.G. Nomikos, P. Carter, F.P. Bymaster, A.B. Leese, and C.C. Felder. 2002. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3):1020-1024.
222. Pryce, G., G. Giovannoni, and D. Baker. 2003. Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabionol in mice. Neurosci Lett 341(2):164-166.
223. Pryor, G.T., S. Husain, and C. Mitoma. 1976. Acute and subacute interactions between delta-9-tetrahydrocannabinol and other drugs in the rat. Ann N Y Acad Sci 281:171-189.
224. Racz, I., A. Bilkei-Gorzo, Z.E. Toth, K. Michel, M. Palkovits, and A. Zimmer. 2003. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 23(6):2453-2458.
225. Ralevic, V., and D.A. Kendall. 2001. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 418(1-2):117-125.
226. Recht, L.D., R. Salmonsen, R. Rosetti, T. Jang, G. Pipia, T. Kubiatowski, P. Karim, A.H. Ross, R. Zurier, N.S. Litofsky, and S. Burstein. 2001. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 62(6):755-763.
227. 9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 46(1-2):100-108.
228. Roques, B. 1998. Problemes posées par la dangerosité des drogues. Rapport du professeur Bernhard Roques au Secrétaire d'Etat à la Santé. Paris.
229. Rubino, T., D. Vigano, B. Costa, M. Colleoni, and D. Parolaro. 2000. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. J Neurochem 75(6):2478-2484.
230. Rubino, T., D. Vigano, P. Massi, and D. Parolaro. 2000. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55, 940. J Neurochem 75(5):2080-2086.
231. Russo, E., M.L. Mathre, A. Byrne, R. Velin, P.J. Bach, J. Sanchez-Ramos, and K.A. Kirlin. 2002. Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal medical cannabis. J Cannabis Ther 2(1):3-57.
232. Sallan, S.E., C. Cronin, M. Zelen, and N.E. Zinberg. 1980. Antiemetics in patients receiving chemotherapy for cancer: A randomized comparison of delta-9-tetra-hydrocannabinol and prochlorperazine. N Engl J Med 302(3):135-138.
233. Sanchez, C., M.L. de Ceballos, T.G. del Pulgar, D. Rueda, C. Corbacho, G. Velasco, I. Galve-Roperh, J.W. Huffman, S. Ramon y Cajal, and M. Guzman. 2001. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61(15):5784-5789.
234. Sandyk, R., and G. Awerbuch. 1998. Marijuana and Tourette's syndrome. J Clin Psychopharmacol 8:844.
235. Sañudo-Peña, M.C., K. Tsou, and J.M. Walker. 1999. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65:703-713.
236. Schnelle, M., F. Grotenhermen, M. Reif, and R.W. Gorter. 1999. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von Canna-bisprodukten im deutschen Sprachraum, [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. (Suppl 3) 28-36. Forsch Komplementarmed [Res Complementary Med] (Suppl 3) 28-36.
237. Shook, J.E., and T.F. Burks. 1989. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 249(2):444-449.
238. Showalter, V.M., D.R. Compton, B.R. Martin, and M.E. Abood. 1996. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278(3):989-999.
239. Siegling, A., H.A. Hofmann, D. Denzer, F. Mauler, and J. De Vry. 2001. Canna-binoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 415(1):R5-R7.
240. Sieradzan, K.A., S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie. 2001. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 57(11):2108-2111.
241. Slikker, W. Jr., M.G. Paule, S.F. Ali, A.C. Scallet, and J.R. Bailey. 1992. Behavioral, neurochemical and neurhistochemical effects of chronic marijuana smoke exposure in the nonhuman primate. In L. Myrphy and A. Bartke (eds.), Marijuana/Cannabinoids: Neurobiology and neurophysiology (pp. 219-73). Boca Raton, FL: CRC Press.
242. Smith, C.G., R.G. Almirez, J. Berenberg, and R. H. Asch. 1983. Tolerance develops to the disruptive effects of delta 9-tetrahydrocannabinol on primate menstrual cycle. Science 219(4591):1453-1455.
243. Soderpalm, A.H., A. Schuster, and H. de Wit. 2001. Antiemetic efficacy of smoked marijuana: Subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 69(3-4):343-350.
244. 9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther 186(3):646-655.
245. Solowij, N., and B.F.S. Grenyer. 2002b. Long term effects of cannabis on psyche and cognition. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 299-312). Binghamton, NY: The Haworth Press.
246. Solowij, N., R.S. Stephens, R.A. Roffman, T. Babor, R. Kadden, M. Miller, K. Christiansen, B. McRee, and J. Vendetti. 2002. Cognitive Functioning of Longterm Heavy Cannabis Users Seeking Treatment. JAMA 287(9):1123-1131.
247. Stefanis, C. 1978. Biological aspects of cannabis use. NIDA Res Monogr 19:149-178.
248. Stockings, G.T. 1947. A new euphoriant for depressive mental states. BMJ 1:918-922.
249. Sugiura, T., S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku. 1995. 2-Arachidonoylglycerol: A possible endogenous canna-binoid receptor ligand in brain. Biochem Biophys Res Commun 215(1):89-97.
250. Sulcova, E., R. Mechoulam, and E. Fride. 1998. Biphasic effects of anandamide. Pharmacol Biochem Behav 59(2):347-352.
251. 9-THC) with drugs and anesthetics. In G. Nahas, K.M. Sutin, D.J. Harvey, and S. Agurell (eds.), Marihuana and medicine (pp. 253-271). Totowa, NJ: Humana Press.
252. Szabo, B., U. Nordheim, and N. Niederhoffer. 2001. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297:819-826.
253. Tahir, S.K., J.E. Trogadis, J.K. Stevens, and A.M. Zimmerman. 1992. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol 70(10-11):1159-1173.
254. Tanda, G., F.E. Pontieri, and G. Di Chiara. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276(5321):2048-2050.
255. Tashkin, D.P., J.A. Levisman, A.S. Abbasi, B.J. Shapiro, and N.M. Ellis. 1977. Short-term effects of smoked marihuana on left ventricular function in man. Chest 72(1):20-26.
256. 9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis 109(4):420-428.
257. Terranova, J.-P., J.-J. Storme, N. Lafon, A. Perio, Rinaldi-Carmona, G. Le Fur, and P. Soubrie. 1996. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 126:165-172.
258. Thompson, G.R., H. Rosenkrantz, U.H. Schaeppi, and M.C. Braude. 1973. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 25(3):363-372.
259. Thompson, L.J., and R.C. Proctor. 1953. The use of pyrahexyl in the treatment of alcoholic and drug withdrawal conditions. N Carolina Med J 14:520-523.
260. Titishov, N., R. Mechoulam, and A.M. Zimmerman. 1989. Stereospecific effects of (-)- and (+)-7-hydroxy-delta-6-tetrahydrocannabinol-dimethylheptyl on the immune system of mice. Pharmacology 39(6):337-349.
261. Toyota, M., T. Shimamura, H. Ishii, M. Renner, J. Braggins, and Y. Asakawa. 2002. New bibenzyl cannabinoid from the New Zealand liverwort Radula marginata. Chem Pharm Bull (Tokyo) 50(10):1390-1392.
262. Ungerleider, J.T., T. Andyrsiak, L. Fairbanks, G.W. Ellison, and L.W. Myers. 1987. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7(1):39-50.
263. Vacca, G., S. Serra, G. Brunetti, M.A. Carai, G.L. Gessa, and G. Colombo. 2002. Boosting effect of morphine on alcohol drinking is suppressed not only by naloxone but also by the cannabinoid CB1 receptor antagonist, SR 141716. Eur J Pharmacol 445(1-2):55-59.
264. Van der Stelt, M., W.B. Veldhuis, P.R. Bar, G.A. Veldink, J.F. Vliegenthart, and K. Nicolay. 2001. Neuroprotection by delta-9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21(17):6475-6479.
265. Van Klingeren, B., and M. Ten Ham. 1976. Antibacterial activity of delta-9-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek 42(1-2):9-12.
266. Volicer, L., M. Stelly, J. Morris, J. McLaughlin, and B.J. Volicer. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12(9):913-919.
267. Wachtel, S.R., and H. de Wit. 2000. Naltrexone does not block the subjective effects of oral Δ9-tetrahydrocannabinol in humans. Drug Alcohol Depend 59(3):251-260.
268. Wachtel, S.R., M.A. ElSohly, S.A. Ross, J. Ambre, and H. De Wit. 2002. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 161(4):331-339.
269. Wade, D.T., P. Robson, H. House, P. Makela, and J. Aram. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17:18-26.
270. Wagner, J.A., K. Hu, J. Karcher, J. Bauersachs, A. Schafer, M. Laser, H. Han, and G. Ertl. 2003. CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 138(7):1251-1258.
271. Wagner, J.A., Z. Jarai, S. Batkai, and G. Kunos. 2001. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423(2-3):203-210.
272. Wagner, J.A., K. Varga, and G. Kunos. 1998. Cardiovascular actions of canna-binoids and their generation during shock. J Mol Med 76(12):824-836.
273. Walker, J.M., S.M. Huang, N.M. Strangman, K. Tsou, and M.C. Sanudo-Pena. 1999. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96(21):12198-12203.
274. Welch, S.P., and M. Eads. 1999. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 848(1-2):183-190.
275. Wiley, J.L., and B.R. Martin. 2002. Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121(1-2):57-63.
276. Williams, C.M., and T.C. Kirkham. 1999. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143(3):315-317.
277. Williams, C.M., and T.C. Kirkham. 2002. Observational analysis of feeding induced by Delta(9)-THC and anandamide. Physiol Behav 76(2):241-250.
278. Williams, S.J., J.P. Hartley, and J.D. Graham. 1976. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 31(6):720-773.
279. Yuan, M., S.M. Kiertscher, Q. Cheng, R. Zoumalan, D.P. Tashkin, and M.D. Roth. 2002. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133(1-2):124-131.
280. Zuardi, A.W., F.S. Guimarães, V.M.C. Guimarães, and E.A. Del Bel. 2002. Cannabidiol: Possible therapeutic application. In F. Grotenhermen and E. Russo (eds.), Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential (pp. 359-370). Binghamton, NY: The Haworth Press.
281. Zuardi, A.W., I. Shirakawa, E. Finkelfarb, and I.G. Karniol. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245-250.
282. Zullino, D.F., D. Delessert, C.B. Eap, M. Preisig, and P. Baumann. 2002. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 17(3):141-143.
283. Adriani, W., A. Caprioli, O. Granstrem, M. Carli, and G. Laviola. 2003. The spontaneously hypertensive-rat as an animal model of ADHD: Evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev 27 (7):639-651.
284. Attal, N., L. Brasseur, D. Guirimand, S. Clermond-Gnamien, S. Atlami, and D. Bouhassira. 2004. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 8 (2):173-177.
285. Berman, J. S., C. Symonds, and R. Birch. 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (3):299-306.
286. Brady, C. M., R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, and C. J. Fowler. 2004. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10 (4):425-433.
287. Habayeb, O.M., A. H. Taylor, M.D. Evans, M. S. Cooke, D. J. Taylor, S. C. Bell, and J. C. Konje. 2004. Plasma levels of the endocannabinoid anandamide in women-A potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab 89 (11):5482-5487.
288. Hezode, C., F. Roudot-Thoraval, S. Nguyen, P. Grenard, B. Julien, E. S. Zafrani, J. M. Pawlostky, D. Dhumeaux, S. Lotersztajn, and A. Mallat. 2005. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42(1):63-71.
289. Hill, M. N., S. Patel, E. J. Carrier, D. J. Rademacher, B. K. Ormerod, C. J. Hillard, and B. B. Gorzalka. 2005. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30 (3):508-15.
290. Julien, B., P. Grenard, F. Teixeira-Clerc, J. T. Van Nhieu, L. Li, M. Karsak, A. Zimmer, A. Mallat, and S. Lotersztajn. 2005. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 (3):742-755.
291. Lange, J. H., and C. G. Kruse. 2004. Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Devel 7 (4):498-506.
292. Mbvundula, E. C., R. A. Bunning, and K. D. Rainsford. 2005. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochem Pharmacol 69 (4):635-640.
293. Mestre, L., F. Correa, A. Arevalo-Martin, E. Molina-Holgado, M. Valenti, G. Ortar, V. Di Marzo, and C. J. Guaza. 2005. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 92 (6):1327-1339.
294. Ni, X., E. B. Geller, M. J. Eppihimer, T. K. Eisenstein, M. W. Adler, and R. F. Tuma. 2004. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10 (2):158-164.
295. Notcutt, W., M. Price, R. Miller, S. Newport, C. Phillips, S. Simmons, and C. Sansom. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59 (5):440-452.
296. Patel, S., C. T. Roelke, D. J. Rademacher, W. E. Cullinan, and C. J. Hillard. 2004. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (12):5429-5430.
297. Ramirez, B. G., C. Blazquez, T. Gomez del Pulgar, M. Guzman, and M. L. de Ceballos. 2005. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25 (8):1904-1913.
298. Svendsen, K. B., T. S. Jensen, and F. W. Bach. 2004. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329 (7460):253.
299. Vaney, C., M. Heinzel-Gutenbrunner, P. Jobin, F. Tschopp, B. Gattlen, U. Hagen, M. Schnelle, and M. Reif. 2004. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10 (4):417-424.
300. Vinod, K.Y., V. Arango, S. Xie, S. A. Kassir, J. J. Mann, T. B. Cooper, and B. L. Hungund. 2005. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 57 (5):480-486.
301. Wade, D.T., P. Makela, P. Robson, H. House, and C. Bateman. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10 (4):434-441.
302. Zajicek, J. 2004. The cannabinoids in MS study-Final results from 12 months follow-up. Mult Scler 10 (suppl 2):115.
303. Zajicek, J., P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, and A. Thompson. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362 (9395):1517-1526.